IIPR reported total revenues of $62.9 million for Q2 2025, a 12% sequential decrease, attributed to previously disclosed tenant defaults. Adjusted funds from operations (AFFO) for the quarter was ...

Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could ...

Private capital firms focused on investment and operations within the Life Science and Healthcare industries face complex compliance, operational, ...

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), ...